Skip Navigation

Non-Alcoholic Steatohepatitis (NASH)

printer friendly version

A phase 2b, dose-ranging, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of GS-6624, a monoclonal antibody against lysyl oxidase-like 2 (LOXL2), in subjects with advanced liver fibrosis but not cirrhosis secondary to non-alcoholic steatohepatitis (NASH)


Enrollment Status: OPEN



To determine if injectable study drug (simtuzumab, GS-6624) is effective at preventing the progression of liver fibrosis in subjects with non-cirrhotic NASH.

Inclusion criteria

Exclusion criteria

Study Design

Contacts for referrals and questions:

Principal Investigator: Robert Fontana, MD –